Save over 55% with Gavreto from Europe
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe:
Roche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Information about Gavreto (Pralsetinib)
Gavreto is a targeted therapy used to treat certain types of cancers characterized by RET (rearranged during transfection) gene alterations. It is an oral tyrosine kinase inhibitor designed to inhibit RET signaling pathways, which play a crucial role in tumor growth.
Product Highlights
- FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer.
- Treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) that is RET fusion-positive.
- Treatment for adult and pediatric patients aged 12 years and older with advanced or metastatic medullary thyroid cancer harboring RET mutations.
Key Ingredient
Key Benefits
- Targets RET alterations specifically, providing a more personalized treatment option.
- Can lead to significant tumor shrinkage and prolonged disease control in eligible patients.
- Generally well-tolerated with a manageable safety profile.
Direction of Use
- Take one tablet daily, with or without food.
- Swallow the tablet whole; do not crush or chew.
- Adhere to the prescribed dosage as instructed by your healthcare provider.
Safety Concerns
- Potential side effects include hypertension, fatigue, diarrhea, liver enzyme elevations, and QT interval prolongation.
- Routine monitoring of blood pressure and liver function tests is advised.
Avoid Gavreto (Pralsetinib) If
- You have a known hypersensitivity to pralsetinib or any of its components.
- You are pregnant or plan to become pregnant; effective contraception is advised during treatment.
- You are taking medications that may interact adversely with pralsetinib, particularly those affecting liver enzymes.
